Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo
Gastric cancer is one of the most common malignancies diagnosed worldwide. Telmisartan, an angiotensin receptor blocker (ARB), suppresses the proliferation of cancer cells and the growth of tumors through an unknown mechanism. To identify the mechanism, the present study was designed to evaluate the effects of telmisartan on gastric cancer cell lines and tumors in vitro and in vivo and the associated signaling molecules were identified. It was shown here that telmisartan suppressed the proliferation of the cultured human gastric cancer cell lines MKN74, MKN1 and MKN45 as detected in the CCK‑8 assay. In a mouse xenograft model of gastric cancer, telmisartan suppressed tumor growth by arresting the cell cycle at the G0/G1 phase through inhibition of the expression of cyclin D1, the catalytic subunit of cyclin dependent kinase 4 (CDK4), as well as the phosphorylation of the tumor suppressor retinoblastoma (pRb) protein as detected by western blotting. Notably, telmisartan did not induce apoptosis, as indicated by consistent levels of caspase‑cleaved keratin 18 in MKN74 cells. Furthermore, telmisartan inhibited the phosphorylation of epidermal growth factor receptor (EGFR) and increased the levels of the angiogenesis‑related protein tissue inhibitor of metalloproteinase‑1 (TIMP‑1). Analyses of microarrays revealed that telmisartan altered the expression of miRNAs in MKN74 cells. In conclusion, telmisartan suppressed the proliferation of human gastric cancer cells by inducing cell cycle arrest.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Oncology reports - 44(2020), 1 vom: 24. Juli, Seite 339-348 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fujita, Naoki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2021 Date Revised 22.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3892/or.2020.7607 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312047444 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312047444 | ||
| 003 | DE-627 | ||
| 005 | 20231225143555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/or.2020.7607 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312047444 | ||
| 035 | |a (NLM)32627043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fujita, Naoki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2021 | ||
| 500 | |a Date Revised 22.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Gastric cancer is one of the most common malignancies diagnosed worldwide. Telmisartan, an angiotensin receptor blocker (ARB), suppresses the proliferation of cancer cells and the growth of tumors through an unknown mechanism. To identify the mechanism, the present study was designed to evaluate the effects of telmisartan on gastric cancer cell lines and tumors in vitro and in vivo and the associated signaling molecules were identified. It was shown here that telmisartan suppressed the proliferation of the cultured human gastric cancer cell lines MKN74, MKN1 and MKN45 as detected in the CCK‑8 assay. In a mouse xenograft model of gastric cancer, telmisartan suppressed tumor growth by arresting the cell cycle at the G0/G1 phase through inhibition of the expression of cyclin D1, the catalytic subunit of cyclin dependent kinase 4 (CDK4), as well as the phosphorylation of the tumor suppressor retinoblastoma (pRb) protein as detected by western blotting. Notably, telmisartan did not induce apoptosis, as indicated by consistent levels of caspase‑cleaved keratin 18 in MKN74 cells. Furthermore, telmisartan inhibited the phosphorylation of epidermal growth factor receptor (EGFR) and increased the levels of the angiogenesis‑related protein tissue inhibitor of metalloproteinase‑1 (TIMP‑1). Analyses of microarrays revealed that telmisartan altered the expression of miRNAs in MKN74 cells. In conclusion, telmisartan suppressed the proliferation of human gastric cancer cells by inducing cell cycle arrest | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a telmisartan | |
| 650 | 4 | |a cyclin | |
| 650 | 4 | |a microRNA | |
| 650 | 4 | |a angiotensin II type 1 receptor blocker | |
| 650 | 4 | |a cell cycle arrest | |
| 650 | 4 | |a receptor tyrosine kinase | |
| 650 | 4 | |a angiogenesis | |
| 650 | 7 | |a CCND1 protein, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a Retinoblastoma Protein |2 NLM | |
| 650 | 7 | |a Cyclin D1 |2 NLM | |
| 650 | 7 | |a 136601-57-5 |2 NLM | |
| 650 | 7 | |a CDK4 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Telmisartan |2 NLM | |
| 650 | 7 | |a U5SYW473RQ |2 NLM | |
| 700 | 1 | |a Fujita, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Iwama, Hisakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Kobara, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujihara, Shintaro |e verfasserin |4 aut | |
| 700 | 1 | |a Chiyo, Taiga |e verfasserin |4 aut | |
| 700 | 1 | |a Namima, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yamana, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Kono, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Takuma, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Kiyoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Kiyohito |e verfasserin |4 aut | |
| 700 | 1 | |a Kamada, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Morishita, Asahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tsutsui, Kunihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Himoto, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Okano, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yasuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Masaki, Tsutomu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology reports |d 1994 |g 44(2020), 1 vom: 24. Juli, Seite 339-348 |w (DE-627)NLM09366334X |x 1791-2431 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2020 |g number:1 |g day:24 |g month:07 |g pages:339-348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/or.2020.7607 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2020 |e 1 |b 24 |c 07 |h 339-348 | ||